MSK Department of Medicine
@mskdeptofmed.bsky.social
The official account of @mskcancercenter.bsky.social's Department of Medicine. Chair/Dept. Head: Deb Schrag
Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.
The @fda.gov approved the immunotherapy epcoritamab-bysp with lenalidomide and rituximab for relapsed or refractory follicular lymphoma: buff.ly/JNJZKMb
FDA approves epcoritamab-bysp for follicular lymphoma indications
FDA approves epcoritamab-bysp for follicular lymphoma indications
www.fda.gov
November 18, 2025 at 7:14 PM
Congratulations to Dr. Lorenzo Falchi of @mskcancercenter.bsky.social on the FDA approval of epcoritamab-bysp with lenalidomide and rituximab for adults with relapsed or refractory follicular #lymphoma! A huge win for those with the condition. Dr. Falchi will present phase 3 trial data at #ASH25.
Reposted by MSK Department of Medicine
At New York Lung, Charlie Rudin @mskdeptofmed.bsky.social showing trials and investigators representing future approaches in small cell lung cancer @jessieross.bsky.social
November 15, 2025 at 3:51 PM
At New York Lung, Charlie Rudin @mskdeptofmed.bsky.social showing trials and investigators representing future approaches in small cell lung cancer @jessieross.bsky.social
Out in @bmjmedicine.bsky.social: Dr. Corita Grudzen & team examined whether follow-up palliative care via outpatient visits or nurse-led phone calls led to better outcomes for seriously ill adults who recently visited the emergency department. @mskcancercenter.bsky.social
➡️ bit.ly/48bhFOx
➡️ bit.ly/48bhFOx
November 14, 2025 at 8:36 PM
Out in @bmjmedicine.bsky.social: Dr. Corita Grudzen & team examined whether follow-up palliative care via outpatient visits or nurse-led phone calls led to better outcomes for seriously ill adults who recently visited the emergency department. @mskcancercenter.bsky.social
➡️ bit.ly/48bhFOx
➡️ bit.ly/48bhFOx
Reposted by MSK Department of Medicine
In this manuscript, online today in Cancer Discovery, we investigate target-mediated resistance to ADCs, and propose ways to overcome it.
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding
Abstract. T-DXd is clinically beneficial in HER2 positive and HER2 low metastatic breast cancer. However, therapeutic resistance emerges over time in most patients, with poorly defined resistance mech...
aacrjournals.org
November 10, 2025 at 4:55 PM
In this manuscript, online today in Cancer Discovery, we investigate target-mediated resistance to ADCs, and propose ways to overcome it.
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
Reposted by MSK Department of Medicine
Now online in Cancer Discovery @aacrjournals.bsky.social: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding - by Wanyi Chen, @joshdragomd.bsky.social, @saratchandarlapaty.bsky.social, and colleagues doi.org/10.1158/2159... @mskcancercenter.bsky.social
November 10, 2025 at 6:15 PM
Now online in Cancer Discovery @aacrjournals.bsky.social: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding - by Wanyi Chen, @joshdragomd.bsky.social, @saratchandarlapaty.bsky.social, and colleagues doi.org/10.1158/2159... @mskcancercenter.bsky.social
Reposted by MSK Department of Medicine
Here, Dr. Pedram Razavi explains MSK's efforts to prevent drug resistance from developing in #breastcancer patients. A new study seeks to anticipate the malignant cells' next move, like playing poker with cancer and being able to see most of its cards.
Learn more: bit.ly/47cxyDZ
Learn more: bit.ly/47cxyDZ
October 28, 2025 at 4:32 PM
Here, Dr. Pedram Razavi explains MSK's efforts to prevent drug resistance from developing in #breastcancer patients. A new study seeks to anticipate the malignant cells' next move, like playing poker with cancer and being able to see most of its cards.
Learn more: bit.ly/47cxyDZ
Learn more: bit.ly/47cxyDZ
Reposted by MSK Department of Medicine
Congratulations to this year’s recipients of the MSK 2025 Paul Marks Prize for Cancer Research: Dr. @oawlab.bsky.social, of MSK; Dr. Andrea Ablasser, of EPFL; and Dr. Christina Curtis, of @stanfordmedicine.bsky.social.
Learn more about the winners: bit.ly/47y8HLb
Learn more about the winners: bit.ly/47y8HLb
November 4, 2025 at 2:42 PM
Congratulations to this year’s recipients of the MSK 2025 Paul Marks Prize for Cancer Research: Dr. @oawlab.bsky.social, of MSK; Dr. Andrea Ablasser, of EPFL; and Dr. Christina Curtis, of @stanfordmedicine.bsky.social.
Learn more about the winners: bit.ly/47y8HLb
Learn more about the winners: bit.ly/47y8HLb
Reposted by MSK Department of Medicine
Important translational and clinical work here using CD40 agonistic antibody in metastatic cancer @anatosaurus.bsky.social Cancer Cell www.cell.com/cancer-cell/... @mskcancercenter.bsky.social @mskdeptofmed.bsky.social
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer
Osorio et al. report a first-in-human study of intratumoral 2141-V11, an Fc-engineered
CD40 agonistic antibody, showing it is safe and induces systemic and durable antitumor
immunity in patients with ...
www.cell.com
October 29, 2025 at 3:36 PM
Important translational and clinical work here using CD40 agonistic antibody in metastatic cancer @anatosaurus.bsky.social Cancer Cell www.cell.com/cancer-cell/... @mskcancercenter.bsky.social @mskdeptofmed.bsky.social
Reposted by MSK Department of Medicine
We're excited to share that we've been recognized as #1 in oncology on @newsweek.com's World's Best Specialized Hospitals List.
bit.ly/4nefIFv
bit.ly/4nefIFv
October 22, 2025 at 4:58 PM
We're excited to share that we've been recognized as #1 in oncology on @newsweek.com's World's Best Specialized Hospitals List.
bit.ly/4nefIFv
bit.ly/4nefIFv
Reposted by MSK Department of Medicine
MSK experts are investigating whether #brachytherapy may be an effective treatment option for reducing local recurrence, lowering the risk of #necrosis associated with standard #radiation, and improving the quality of life for patients with brain #metastases. Learn more ⬇️
Brachytherapy for Brain Metastases
As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease.
www.mskcc.org
October 23, 2025 at 3:24 PM
MSK experts are investigating whether #brachytherapy may be an effective treatment option for reducing local recurrence, lowering the risk of #necrosis associated with standard #radiation, and improving the quality of life for patients with brain #metastases. Learn more ⬇️
Reposted by MSK Department of Medicine
Excited to announce a new publication from our @mskcancercenter.bsky.social Histiocytosis group identifying a predictor for impaired response to MEK inhibition in histiocytosis patients and potential for ERK inhibition. Out today in @Cancer_Cell.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition
Histiocytic neoplasms are clonal disorders of the monocyte/macrophage lineage defined by mutations activating mitogen-activated protein kinase (MAPK) …
www.sciencedirect.com
October 23, 2025 at 3:26 PM
Excited to announce a new publication from our @mskcancercenter.bsky.social Histiocytosis group identifying a predictor for impaired response to MEK inhibition in histiocytosis patients and potential for ERK inhibition. Out today in @Cancer_Cell.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Reposted by MSK Department of Medicine
We're excited to share that Dr. Omar Abdel-Wahab, a leukemia specialist at MSK, has been elected to the @nam.edu.
With Dr. Abdel-Wahab’s appointment, a total of 28 MSK faculty members have been conferred with this recognition.
Congratulations, Dr. Abdel-Wahab!
bit.ly/49ezKw0
With Dr. Abdel-Wahab’s appointment, a total of 28 MSK faculty members have been conferred with this recognition.
Congratulations, Dr. Abdel-Wahab!
bit.ly/49ezKw0
Memorial Sloan Kettering Cancer Center Physician-Scientist Elected to the Prestigious National Academy of Medicine
Omar Abdel-Wahab, MD, Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI); Evnin Family Chair in Molecular Pharmacology and Attending Physician on the Leukemia Service at Me...
bit.ly
October 21, 2025 at 5:49 PM
We're excited to share that Dr. Omar Abdel-Wahab, a leukemia specialist at MSK, has been elected to the @nam.edu.
With Dr. Abdel-Wahab’s appointment, a total of 28 MSK faculty members have been conferred with this recognition.
Congratulations, Dr. Abdel-Wahab!
bit.ly/49ezKw0
With Dr. Abdel-Wahab’s appointment, a total of 28 MSK faculty members have been conferred with this recognition.
Congratulations, Dr. Abdel-Wahab!
bit.ly/49ezKw0
#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib plus pembrolizumab in advanced #endometrialcancer. @mskcancercenter.bsky.social
➡️ bit.ly/3JncnWA
➡️ bit.ly/3JncnWA
October 21, 2025 at 3:28 PM
#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib plus pembrolizumab in advanced #endometrialcancer. @mskcancercenter.bsky.social
➡️ bit.ly/3JncnWA
➡️ bit.ly/3JncnWA
Reposted by MSK Department of Medicine
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myesmo.bsky.social Congress 2025 held in Berlin. Highlights include the latest updates on phase 1 trials testing innovative treatment approaches for select patients w/ advanced solid tumors and more:
ESMO 2025 Research Roundup: MSK Presents Exciting Advances in Medical Oncology Research
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the ESMO Congress 2025. Highlights included the latest updates on three phase 1 trials testing innovative...
www.mskcc.org
October 20, 2025 at 6:07 PM
MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myesmo.bsky.social Congress 2025 held in Berlin. Highlights include the latest updates on phase 1 trials testing innovative treatment approaches for select patients w/ advanced solid tumors and more:
This morning at #ESMO25, William Tap gave a special symposium presentation on how to use biology to guide the development of novel therapies for #sarcoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/47h3DJG
Learn more: bit.ly/47h3DJG
October 20, 2025 at 1:19 PM
This morning at #ESMO25, William Tap gave a special symposium presentation on how to use biology to guide the development of novel therapies for #sarcoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/47h3DJG
Learn more: bit.ly/47h3DJG
At #ESMO25, join Dr. Yonina Murciano-Goroff to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/4nafnUa
Learn more: bit.ly/4nafnUa
October 19, 2025 at 12:30 PM
At #ESMO25, join Dr. Yonina Murciano-Goroff to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/4nafnUa
Learn more: bit.ly/4nafnUa
Happening NOW at #ESMO25: View Kenneth Yu's poster about a phase 1 trial of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells for stage 4 #pancreaticcancer or #breastcancer with an inherited BRCA/PALB2 mutation.
@mskcancercenter.bsky.social
Learn more: bit.ly/3KZ0iHw
@mskcancercenter.bsky.social
Learn more: bit.ly/3KZ0iHw
October 19, 2025 at 10:00 AM
Happening NOW at #ESMO25: View Kenneth Yu's poster about a phase 1 trial of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells for stage 4 #pancreaticcancer or #breastcancer with an inherited BRCA/PALB2 mutation.
@mskcancercenter.bsky.social
Learn more: bit.ly/3KZ0iHw
@mskcancercenter.bsky.social
Learn more: bit.ly/3KZ0iHw
At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
October 18, 2025 at 5:02 PM
At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
Happening tomorrow at #ESMO25: Helena Yu will share preliminary results from the ongoing phase 2b trial of zipalertinib in patients with non-small cell #lungcancer who have central nervous system #metastases. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W74yY3
Learn more: bit.ly/3W74yY3
October 18, 2025 at 4:03 PM
Happening tomorrow at #ESMO25: Helena Yu will share preliminary results from the ongoing phase 2b trial of zipalertinib in patients with non-small cell #lungcancer who have central nervous system #metastases. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W74yY3
Learn more: bit.ly/3W74yY3
Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3WcyfH5
Learn more: bit.ly/3WcyfH5
October 18, 2025 at 3:02 PM
Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3WcyfH5
Learn more: bit.ly/3WcyfH5
Don't miss the first presidential symposium at #ESMO25! Tomorrow, join @DrRosenbergMSK to hear his thoughts on a study of perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive #bladdercancer. @mskcancercenter.bsky.social
Learn more: bit.ly/42JM3ws
Learn more: bit.ly/42JM3ws
October 17, 2025 at 6:30 PM
Don't miss the first presidential symposium at #ESMO25! Tomorrow, join @DrRosenbergMSK to hear his thoughts on a study of perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive #bladdercancer. @mskcancercenter.bsky.social
Learn more: bit.ly/42JM3ws
Learn more: bit.ly/42JM3ws
Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W6rqqz
Learn more: bit.ly/3W6rqqz
October 17, 2025 at 5:03 PM
Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W6rqqz
Learn more: bit.ly/3W6rqqz
Tomorrow at #ESMO25, Violaine Randrian will present a study investigating whether the mechanism of mismatch repair protein loss impacts outcomes for those with solid tumors treated with #immunotherapy. @mskcancercenter.bsky.social
Learn more: bit.ly/4neLsu1
🗓️ October 18 | 11:10 a.m. CEST
Learn more: bit.ly/4neLsu1
🗓️ October 18 | 11:10 a.m. CEST
October 17, 2025 at 3:04 PM
Tomorrow at #ESMO25, Violaine Randrian will present a study investigating whether the mechanism of mismatch repair protein loss impacts outcomes for those with solid tumors treated with #immunotherapy. @mskcancercenter.bsky.social
Learn more: bit.ly/4neLsu1
🗓️ October 18 | 11:10 a.m. CEST
Learn more: bit.ly/4neLsu1
🗓️ October 18 | 11:10 a.m. CEST
Congratulations to Ross Levine on his new role as @mskcancercenter.bsky.social's Chief Scientific Officer!
Exciting news: Dr. Ross Levine, Senior Vice President of Translational Research at MSK, has been named MSK's new Chief Scientific Officer (CSO).
Congratulations, Dr. Levine!
bit.ly/4hfeWq7
Congratulations, Dr. Levine!
bit.ly/4hfeWq7
October 16, 2025 at 5:55 PM
Congratulations to Ross Levine on his new role as @mskcancercenter.bsky.social's Chief Scientific Officer!
Exciting research is ahead at #ESMO25! Tomorrow, Dr. Michael Foote will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/4qrq3Rg
Learn more: bit.ly/4qrq3Rg
October 16, 2025 at 1:02 PM
Exciting research is ahead at #ESMO25! Tomorrow, Dr. Michael Foote will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/4qrq3Rg
Learn more: bit.ly/4qrq3Rg